Departments of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
Hepatol Res. 2007 Sep;37 Suppl 2:S210-5. doi: 10.1111/j.1872-034X.2007.00187.x.
Several staging systems have been developed to classify patients with hepatocellular carcinoma (HCC), however, there is no consensus on which of these is the most useful and reliable. In this review article, currently available integrated staging systems taking into account both liver function and tumor progression are presented, and their characteristics and applicability for current HCC patients, many of whom are diagnosed in the early stage of the disease and treated by curative therapy, are discussed. Based on the original andsubsequent validation studies of these staging systems, we recommend that further validation studies of staging systems for HCC should focus on the revised Barcelona Clinic Liver Cancer (BCLC) staging classification, Japan Integrated Staging (JIS) score and Tokyo score.
已经开发了几种分期系统来对肝细胞癌 (HCC) 患者进行分类,但对于哪种系统最有用和可靠,尚无共识。在这篇综述文章中,介绍了目前可用的综合分期系统,这些系统考虑了肝功能和肿瘤进展情况,并讨论了它们的特点和对目前 HCC 患者的适用性,其中许多患者在疾病的早期被诊断出来并接受治愈性治疗。基于这些分期系统的原始和后续验证研究,我们建议 HCC 分期系统的进一步验证研究应集中在修订后的巴塞罗那临床肝癌 (BCLC) 分期分类、日本综合分期 (JIS) 评分和东京评分上。